BioSante Pharmaceuticals Added to NASDAQ Biotechnology Index

Printer-friendly versionPDF version

LINCOLNSHIRE, Illinois (November 21, 2011)– BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has been added to the NASDAQ Biotechnology Index^®(Symbol: NBI), effective prior to the stock market open today, November 21, 2011.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is a modified market capitalization-weighted index, and the index securities are evaluated semi-annually in May and November.

"We are delighted that BioSante has been added to the NASDAQ Biotechnology Index, as it recognizes our established role in the biotechnology industry, adds greater visibility for our company and could lead to a broader stockholder base," stated Phillip Donenberg, BioSante's senior vice president of finance and chief financial officer.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel^®(transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at:www.biosantepharma.com.

###

For more information please contact:

For Media:
Alan Zachary
Harris D. McKinney
(312) 506-5220

azachary@harrisdmckinney.com

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953

tswanson@troutgroup.com

News Source : BioSante Pharmaceuticals Added to NASDAQ Biotechnology Index